Coughing, sneezing, and high temperature are common signs of a cold. While these may look harmless, they can also be symptoms ...

Just like adults under 60, elderly adults who get RSV tend to have mild symptoms, such as runny nose, sore throat, cough, ...

The following is a summary of “Sex differences in the impact of lower respiratory tract infections on older adults’ health ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Opens in a new tab or window In May, the FDA approved the mRNA-1345 RSV vaccine (mResvia) from Moderna for people ages 60 and older to protect against lower respiratory tract disease. Approval was ...

The vaccine, called Abrysvo, has been approved for the prevention of lower respiratory tract diseases, such as pneumonia and bronchitis, caused by respiratory syncytial virus, or RSV, in people ...

to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 who are at high risk. Abrysvo now offers the broadest RSV vaccine indication for adults, which ...

a subsidiary of Agenus. Indication for AREXVY AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial ...

against lower respiratory tract disease caused by the contagious virus, until they are six months old. RSV symptoms include cough, fever and body aches, and can result in pneumonia and ...